Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced the presentation of new data at The Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC for the investigational protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C in treatment-naive and treatment-experienced adult patients with compensated liver disease. In analyses of the Phase 3 QUEST-1 and QUEST-2 studies in treatment-naive patients and the Phase 3 PROMISE study in prior relapse patients, the efficacy of simeprevir was observed in hepatitis C patients, including patients with the IL28B TT genotype and METAVIR scores of F4.

"Patients with certain baseline characteristics can be more likely to fail or relapse after prior treatment," said Ira Jacobson, M.D., simeprevir clinical trial investigator, chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, Weill Cornell Medical College, and attending physician, New York-Presbyterian Hospital/Weill Cornell Medical Center. "The breadth of simeprevir data presented at AASLD reinforce its potential as a treatment option for patients and will offer important guidance to physicians once simeprevir is approved."   

On October 24, the U.S. Antiviral Drugs Advisory Committee of the FDA voted unanimously (19-0) to recommend approval of the new drug application filed by Janssen Research & Development, LLC for simeprevir administered once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease.

Pooled Analysis from QUEST-1 and QUEST-2 Confirms Clinical Benefit of Simeprevir in Sub-Populations of Patients (Abstract 1122)        
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... N.C., Oct. 31 AlphaVax, Inc.,announced today that it ... of an influenza vaccine based on its proprietary replicon ... properties of this,unique vector system as well as the ... was a placebo-controlled, randomized, double-blind trial in,healthy adults, 18-40 ...
... guide low-income,and minority cancer patients through cancer treatment, ... major obstacles that prevent them,from receiving quality care ... October 28, 2007, at the American Society for ... Angeles. Minority and low-income cancer patients continue ...
Cached Medicine Technology:AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial 2Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments 2
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... found that fecal transplantation is effective and safe for ... is the result of a study led by Colleen ... Gastrointestinal Medicine at The Women,s Medicine Collaborative. The study ... of print in the American Journal of Gastroenterology ... diff , has increased to epidemic proportions over the ...
(Date:7/9/2014)... DALLAS July 9, 2014 There has been ... at UT Southwestern Medical Center using MyChart, the online, ... radiology results, communicate with their healthcare providers, schedule appointments, ... number of patients actively using MyChart each ... each year increased more than 10-fold, according to a ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... WeissComm Group today announced the acquisition of ... company founded by Bob Pearson , who will ... that it has signed a strategic alliance with Rule ... and training. Pearson will continue to operate and grow this ...
... May 27 eCardio Diagnostics ( www.ecardio.com ... is a finalist for the Ernst & Young Entrepreneur ... Houston & Gulf Coast Area Program. According to ... who demonstrate extraordinary success in the areas of innovation, ...
... 27 Autism is a neurobiological condition which is ... some health insurance companies, especially HMOs, fail to cover ... Wellspring, a leader in autism treatment, is excited to ... with their CA health insurance plan to cover autism ...
... term follow-up indicates modest efficacy in primary and ... Ceregene, Inc. today reported additional clinical data ... CERE-120 in 58 patients with advanced Parkinson,s disease. ... the neurotrophic factor, neurturin, to Parkinson,s disease patients ...
... 27 The incidence of cardiovascular disease is ... smoking and other cardiac ailments. Each year cardiovascular ... 48 per cent of all mortalities in Europe.(Logo: ... cardiac rhythm management (CRM) market offers significant growth ...
... laser therapy, is a new treatment that provides proven pain relief and ... offered by The Laser Pain Management Center in Western Massachusetts. , ... ... adverse affect on every aspect of daily life. Low level laser therapy ...
Cached Medicine News:Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 2Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 3Health News:WeissComm Group Acquires Common Sense Media Group, Appoints Founder Bob Pearson Chief Technology and Media Officer to Help Clients Evaluate and Optimize Social Media 4Health News:eCardio Chief Executive Officer Larry Lawson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Finalist in the Houston & Gulf Coast Area Program 2Health News:Wellspring Coordinates With CA Health Insurance Plans to Pay for Autism Treatments 2Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 2Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 3Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 4Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 5Health News:Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan 2Health News:Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan 3Health News:Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan 4Health News:New Non-Surgical Laser Treatment Helps Patients Live Pain Free 2Health News:New Non-Surgical Laser Treatment Helps Patients Live Pain Free 3
... generators are meeting the clinical needs ... and anesthesiologists. And, they are of ... from Medtronic.,Effective pacing with the adjustment ... for quick battery changes. Both ...
... CardioVad is a unique left ventricular assist device ... It is being used in a small group ... as part of an FDA-approved Feasibility Study. The ... the external power source for minutes or hours. ...
... Inc. has introduced the world's first minimally-invasive ... 10626 Epicardial Lead Implant Tool, which has ... States, will expand the options available to ... 5071 lead on the heart during pacemaker ...
The Schiller treadmill ergometer is designed for stress tests, sports medicine and cardiology. It is equipped and tested with the latest safety system and has been manufactured under the stringent qu...
Medicine Products: